May. 8 at 8:04 PM
$NGEN I posted this yesterday, but for some reason didn't show up here. I'm curious what you all think. They say in the corporate presentation that we're starting a new phase 2 clinical trial in about a year, for a new indication for NVG-291. I expect it'll be for TBI, following the preclinical results we'll get soon enough. I believe when it's all done that NVG-291 will be the standard treatment for TBI, but now that there's a push for psychedelics, how do you think that will affect us? The Texas Ibogaine trial got delayed, and I imagine if we run a TBI trial we'll get it done quickly anyway, but I worry about first mover advantage. Realistically, combining SCI and TBI we could make
$5-10 billion yearly, and easily get NVG-300 trials moving.
